NASDAQ$TRML
Tourmaline Bio Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2021 and provided a business update.
Talaris Therapeutics reported its Q2 2021 financial results, highlighting progress with FREEDOM-1 trial and plans for FREEDOM-2 and FREEDOM-3 trials. The company's cash, cash equivalents, and marketable securities totaled $266.2 million, expected to fund operations into 2025.
- On track to provide FREEDOM-1 initial clinical update before year-end.
- Plans to initiate FREEDOM-2 and FREEDOM-3 trials.
- Expects to disclose additional indication for FCR001 before the end of the year.
- Finished the second quarter with $266.2 million in cash, cash equivalents and marketable securities.
Headline financials
Revenue & EPS history
Tourmaline Bio · Revenue · Quarterly
$0
Forward guidance
Talaris Therapeutics is focused on advancing its clinical trials, including FREEDOM-1, FREEDOM-2, and FREEDOM-3, and expects to announce an additional indication for FCR001 before the end of 2021.
Tailwinds
- On track to provide FREEDOM-1 initial clinical update later this year.
- Expanding clinical trial footprint to 14 active sites in the United States.
- Remains on track to initiate a Phase 2 (FREEDOM-2) trial for FCR001 in delayed tolerance induction in the fourth quarter of 2021.
- Remains on track to initiate its first clinical trial in autoimmune diseases with its FREEDOM-3 trial in the fourth quarter of 2021.
- Remains on track to announce an additional target indication for FCR001 relating to a severe non-malignant blood, immune or metabolic disorder before the end of 2021.
Headwinds
- Risks associated with the impact of COVID-19 on the timing and anticipated timing and results of its clinical trials.
- Risk that the results of Talaris’ clinical trials may not be predictive of future results in connection with future clinical trials.
- The Company’s ability to successfully demonstrate the safety and efficacy of its drug candidates.
- The timing and outcome of Talaris’ planned interactions with regulatory authorities.
- Obtaining, maintaining and protecting its intellectual property.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
+0.7%
Avg return
Earnings day
-5.0%
Avg return
5 days after
+13.7%
Avg return
30 days after
59%
10 / 17 earnings
Positive
+11.6%
Q4 2023
Best reaction
-9.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +3.8% | +3.1% | +122.3% | |
| Q1 2025 | +4.6% | +9.9% | +26.5% | |
| Q4 2024 | -2.8% | -4.8% | -1.4% | |
| Q3 2024 | +5.0% | -4.9% | -5.6% | |
| Q2 2024 | +2.0% | +4.6% | +12.2% | |
| Q1 2024 | -0.6% | -4.8% | +2.6% | |
| Q4 2023 | +11.6% | -38.1% | -60.9% | |
| Q3 2023 | -1.2% | — | — | |
| Q2 2023 | +1.3% | — | — | |
| Q1 2023 | -8.0% | — | — | |
| Q4 2022 | +2.8% | — | — | |
| Q3 2022 | +7.0% | — | — | |
| Q2 2022 | -9.7% | — | — | |
| Q1 2022 | +3.1% | — | — | |
| Q4 2021 | +4.6% | — | — | |
| Q3 2021 | -7.0% | — | — | |
| Q2 2021 | -5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro